Abstract Background: Preoperative histologic examination of tumour tissue is essential when deciding if endometrial cancer surgery should include lymph node sampling. We wanted to investigate if biomarkers could improve prediction of lymph node metastasis and outcome. Obstetrics) stage, non-endometrioid histology, high grade and poor prognosis (all P < 0.001). ER/PR loss independently predicted lymph node metastasis (odds ratios (OR) 2.0, 95% confidence interval (CI) 1.1-3.7) adjusted for preoperative curettage histology and predicted poor disease-specific survival adjusted for age, FIGO stage, histologic type, grade and myometrial infiltration (hazard ratio (HR) 2.3, 95% CI 1.4-3.9). For lymph node negative endometrioid tumours, ER/PR loss influenced survival independent of grade. Conclusion: Double negative hormone receptor status in endometrial cancer curettage independently predicts lymph node metastasis and poor prognosis in a prospective multicentre setting. Implementing hormone receptor status to improve risk-stratification for selecting patients unlikely to benefit from lymphadenectomy seems justified.
Introduction
Endometrial cancer is the most common gynaecologic malignancy in industrialised countries. Fifteen to twenty per cent of patients with presumed localised disease at primary treatment recur. 1, 2 Of all patients dying from this disease, one third was initially classified as low risk for recurrence. 3 Contrasting breast cancer, 4, 5 improved knowledge of molecular alterations relevant for prognostication and targeting therapies in endometrial cancer 6, 7 has not been systematically incorporated to tailor therapy. 8 Metastatic lymph nodes detected as part of staging during primary surgery, identifies patients with poor prognosis. 1, 9 Routine lymph node sampling has not confirmed to contribute any survival benefit in randomised studies, 10, 11 but is associated with increased complication rates. 11 Preoperative endometrial biopsy by pipelle or curettage is the cornerstone in diagnostics of endometrial cancer and the first step of treatment algorithm planning for primary surgical treatment. 12 Still, final risk stratification of early stage disease has, until recently, 13 been based on assessing histologic subtype, grade and depth of myometrial infiltration in hysterectomy specimens. 9, 12, 14 Several retrospective studies support that status for oestrogen receptor (ER), progesterone receptor (PR) and the tumour suppressor p53 in primary tumours are independent prognostic markers. 8 This knowledge has not been systematically studied for implementation of individualised surgical therapy in endometrial cancer. 10, 11 Instead, the treatment algorithm has moved towards more aggressive surgery including pelvic and para-aortic lymphadenectomy, 15, 16 despite lack of established criteria and measures for reproducibility, sensitivity and negative predictive value for the procedure. 17 Systematic clinical implementation studies of biomarkers potential useful in surgically staged endometrial cancer patients have been called for. 8 On this background, we have investigated if assessment of ER, PR and p53 in endometrial biopsies, could improve preoperative identification of patients with lymph node metastasis and poor prognosis in the prospective international multicentre trial MoMaTEC (Molecular Markers in Treatment of Endometrial Cancer). 18 
Materials and methods
In total, 1192 consenting endometrial carcinoma patients, have been prospectively recruited from 10 centres for collection of curettage specimens and clinical information between May 2001 through 2010 as previously reported and summarised in Fig. 1 . 18 Distribution of clinicopathologic data is listed in Table 1 . Histologic diagnosis from the routine pathology report and local tumour boards from each centre were utilised. Preoperative curettage histology reports, available for 1166 patients, were classified as low-versus high-risk; the latter including endometrioid grade 3, serous, clear cell, carcinosarcoma and undifferentiated subtypes. The 853 cases preoperatively classified as low-risk included 795 endometrioid grade 1 or 2 tumours and 58 hyperplasias with or without atypia or other, benign diagnoses later confirmed as endometrial carcinoma in hysterectomy specimens. Grading was performed both on the curettage and hysterectomy specimen according to World Health Organization (WHO) classification, based on . table 2   Table 2  Table 3 Nodes positive N = 78 percentage of solid growth and nuclear atypia. Nonendometrioid tumours were all considered as high grade. 19 Pelvic lymph node sampling up to the aorta bifurcation was performed as part of surgical staging in 72% of the patients (n = 856). Para-aortic sampling was done if suspicious nodes were encountered during the operation. Median number of nodes removed was 14 (range 1-72), 10 or more lymph nodes were harvested in 625 (73%), and 105 (12%) had metastatic lymph nodes. The responsible surgeon, blinded for the biomarker study results, decided the extent of sampling, balancing preoperatively known histologic risk factors and the patient's co-morbidity. The patient group without lymph node sampling was significantly older with more superficial myometrial infiltration; otherwise not different from the sampled group (Supplementary Table 1) .
Additional systemic treatment was given to 346 patients (30%), including nearly all patients with FIGO (Federation International of Gynecology and Obstetrics) stages III and IV and half of patients with less advanced stages with endometrioid grade 3 or nonendometrioid subtypes.
Follow-up information regarding recurrence and survival was retrieved as previously reported. 13 Date of last follow-up was December 10th 2012 with mean and median follow-up time for survivors 39 and 38 months (range 0-96). One hundred and forty-four patients died from endometrial carcinoma.
Curettage samples were sufficient for biomarker analyses in 832 women (70%). These were more often endometrioid compared to non-endometrioid (84% versus 76%, P = 0.001) and differentiated (grade 1-2, 71% versus grade 3, 64%, P = 0.017) as compared to tumours with insufficient tissue available. Otherwise patient and tumour characteristics (Supplementary Table 2 ) as well as disease-specific survival (log-rank test P = 0.476) were similar.
Immunohistochemistry and tissue microarray (TMA)
TMAs consisting of triplets from each patient's curettage sample were prepared as described and validated earlier. 20 
Evaluation of staining
Blinded for patient characteristics and outcome, slides were evaluated by two authors (J.T. and H.B.S.) using a standard light microscope. Nuclear staining was scored using a semi-quantitative staining index (range 0-9) as product of staining intensity (score 0-3) and tumour area staining positive (0 = no staining, 1 6 10%, 2 = 10-50% and 3 > 50%), described earlier. 20, 22, 23 In line with the former study, 20 lower quartile of the dataset was applied as cut-off corresponding to staining index 63 for ER and 0 for PR. Pathologic expression of p53 (high) was defined as upper quartile (staining index P4) in line with previous reports. 23, 24 Inter-observer reproducibility was evaluated re-scoring random slides blinded for previous scoring, for 97, 104 and 76 patients respectively, yielding Kappa values of 0.91 for ER, 0.88 for PR and 0.86 for p53 stainings.
Statistical analyses
Assessing the immuno-markers' predictive value for lymph node metastasis was the primary objective, and the prognostic impact the secondary objective of the study. Disease-specific survival was defined as time from surgery to death from endometrial carcinoma. Living patients were censored at last follow-up. Recurrencefree survival was defined as time from surgery to relapse for patients considered cured by primary treatment. Statistical analyses were performed with IBM SPSS 20 program (Statistical Product and Service Solutions version 20.0, IBM, New York) using Pearson's chi-square test exploring associations between categorical variables and binary logistic regression to estimate odds ratios (OR) for lymph node metastasis. Analysis of recurrence-free survival and disease-specific survival was performed by Kaplan-Meyer method and compared using Mantel-Cox (log-rank) test and Cox' proportional hazard method, adjusting for multiple baseline characteristics found significant in the univariate model as previously reported. 23 We tested for potential interactions between variables and examined that hazard functions were proportional over time by log-log plots. All statistical tests were two-sided and considered significant if P < 0.05. Power calculation was done as described in earlier publication regarding the MoMaTEC Trial. 25 
Approvals
Norwegian Data Inspectorate (961478-2), Norwegian Social Science Data Services (15501) 18 and prepared in accordance with STROBE 26 and REMARK recommendations. 27 
Results

Metastatic lymph nodes associate with pathologic expression of curettage biomarkers
Presence of metastatic lymph nodes was significantly associated with histologic features known to correlate Percentage of lymph node metastasis was not significantly different between negative (8.5%) and low (10.6%, P = 0.616).
The hormone receptor stainings in curettage specimens were compared to stainings from n = 364 corresponding hysterectomy TMA specimens. The correlations were highly significant, all P < 0.001 (chi-square test), ER 84% accuracy and PR 88%. ER/PR had 89% accuracy (Supplementary Table 3 ).
Loss of ER and PR expression independently predicts lymph node metastasis
High-risk histology in curettage, loss of ER/PR and pathologic expression of p53, all predicted presence of metastatic lymph nodes in a univariate model (Table 3) . 26% of patients (29 of 113) with combined loss of ER/ PR expression had lymph node metastasis. Double loss of hormone receptors was stronger than p53 in predicting metastatic nodes with OR 3.12 (95% CI 1.87-5.22, P < 0.001). When adjusting for preoperative histology, p53 lost its predictive value, in contrast to ER-/PRstatus being an independent predictor for lymph node metastasis with adjusted OR 2.04 (95% CI 1.12-3.70, P = 0.02, Table 3 ). Using the three category p53 variable (negative, low, high) in the logistic regression regarding lymph node metastasis did not alter the conclusion; p53 was not a significant factor while ERPR loss still had independent OR 2.1 with P = 0.018. For patients presumed as low-risk based on preoperative histology, loss of ER/PR expression predicted lymph node metastasis with adjusted OR 2.89 (95% CI 1.23-6.78, P = 0.015). Combining hormone receptor status and preoperative histology, prediction of metastatic nodes improved: The frequency of metastatic nodes was 8% for low-risk (ER/PR normal and low risk histology), and 23% for patients with either ER/PR loss or highrisk curettage histology with OR 3.33 (95% CI 2.05-5.42), P < 0.001, Table 3 ). Thus selecting for lymph node sampling if either preoperative histology is high risk or hormone receptor staining is negative will increase the sensitivity of detecting metastatic nodes to 0.56 (from 0.43 curettage or 0.37 ER/PR loss if used separately, Table 3 ).
Number nodes sampled correlated with detection of metastatic lymph nodes with an OR 1.04 (95% CI 1.02-1.06) tested as logistic regression. However when adding number of lymph nodes as a factor in the multivariate logistic regression model the OR of ER/PR status is still a significant independent predictor of metastatic lymph nodes with OR 2.2, P = 0.011. Interestingly, OR for curettage risk group based on histology was weakened when adjusted for number of nodes in the model with OR 1.8, 95% CI 0.97-3.3.
In selecting for lymph node sampling or not the histology or grade was not significantly different (Supplementary Table 2 ) but when sampling was performed patients with high risk histology had significantly more lymph nodes sampled (P = 0.004 chi-square test, using median 14 as cut-off). Still we found no survival difference for patients subjected to lymphadenectomy when comparing patients with more than 10 nodes removed to those with less than 10 nodes removed (log-rank test P = 0.876).
Loss of hormone receptors independently predicts poor outcome
Pathologic p53 expression and loss of ER/PR expression, significantly predicted poor disease-specific survival (Supplementary Table 4 , Fig. 3B and C), along with high age, non-endometrioid histology, high grade, high FIGO stage, deep myometrial infiltration and metastatic lymph nodes. There was 14% discrepancy between preoperative and hysterectomy based histologic risk group classification, with 79 changing to high-risk versus 35 changing to low-risk based on hysterectomy evaluation. Preoperative high risk histology identified patients with poor prognosis (Fig. 3A) . A combination of preoperative histology and ER/PR status further refined the identification of poor survivors (Fig. 3D) .
Double negative ER/PR showed independent prognostic impact in Cox survival analysis, adjusted for age, FIGO stage, myometrial infiltration, histologic subtype and grade assessed in hysterectomy specimens, with hazard ratio (HR) 2.28 (95% CI 1.35-3.86, P = 0.002, Table 4 ). p53 lost its independent prognostic impact in this multivariate model. Incorporating p53 as three categories (negative, low, high) in the Cox multivariate model did not alter the conclusion: p53 was not statistical independently significant while ERPR negativity retained HR 2.19 (95% CI 1.29-3.74, P = 0.004).
Interestingly, ER/PR status improved prediction of survival also within prognostic subgroups defined by lymphadenectomy (Fig. 4) . In stratified multivariate analysis among patients without lymph node sampling, double negative ER/PR status predicted poor outcome with HR 4.15 (95% CI 1.60-10.77, P = 0.003) adjusted for age, FIGO stage, myometrial infiltration, histologic subtype and grade. Also for the lymph node negative endometrioid subgroup, ER/PR negative status influenced survival independently of tumour grade with HR 5.36 (95% CI 1.32-21.73, P = 0.019). For endometrioid grade 1-2 patients, a subgroup considered low risk for recurrence; double negative ER/PR was an independent and significant predictor of poor recurrencefree survival with HR 2.80 (95% CI 1.50-5.36, P = 0.002) adjusted for FIGO stage and age.
Discussion
We report for the first time in a large prospective multicentre setting, that hormone receptor loss in preoperative endometrial carcinoma biopsies independently and in addition to preoperative histology, predicts lymph node metastasis.
Lymph node sampling is widely advocated as a compulsory part of complete surgical staging, in particular for intermediate-and high-risk endometrial cancer. 12, 16 No randomised trials have demonstrated any survival benefit from lymphadenectomy, 10,11,28 a procedure associated with prolonged operation time and increased complication rate 11 in an obese and co-morbid patient population. 12 Due to the relatively low frequency of lymph node metastasis and recurrence in low-risk groups, adequately powered randomised surgical trials have been difficult to conduct. Improved tools identifying patients with high risk for lymph node metastasis would reduce the required sample size in a randomised clinical trial of lymphadenectomy, while avoiding potential unnecessary side effects from sampling low-risk patients. Standard preoperative histology carefully assessed to identify patients with high and low risk for aggressive disease should always be the first step in a treatment algorithm. But by applying a combination of preoperative histology and ER/PR status in curettage, we were able to define 69% of the patients as low-risk with only 8% risk of lymph node metastasis but 95% 5-year disease specific survival.
Non-endometrioid subtypes, endometrioid grade 3 and deep myometrial infiltration in the excised uterus have consistently demonstrated to predict lymph node metastasis, 1, 29 in line with our findings. Several methods evaluating myometrial infiltration pre-or perioperatively exist, with variation in reported accuracy for detection of deep infiltration; ranging from 67% to 84% for vaginal ultrasound, 30, 31 47% to 100% for MRI, 32 87% for gross intra-operative inspection 30 and perioperative frozen section evaluation. 33 The 14% discrepancy of preoperative versus final histologic subtype and grade in our study, when dichotomised as high-versus low-risk, is well in line with others ranging from 15% to 32%. [33] [34] [35] Assessment of histologic type and grade in preoperative specimens is considered less reliable compared to hysterectomy evaluation, and 31% verified as high-risk patients based on hysterectomy histopathology was missed preoperatively, illustrating the clinical need for improved tools identifying high-risk cases. Tumour tissue in curettage specimens/preoperative office biopsies are normally more scant than tumour tissue available for evaluation from the removed uterus. Still the sample size available is unlikely to be the whole explanation for this discrepancy as we found and report in Supplementary Table 2 , that the percentage of discordant histologic diagnose (10% change between endometrioid or non-endometrioid histologic type, 14% change between low or highrisk histology (incorporating grade)) was not significantly different whether tissue were successfully retrieved for TMA for further immunohistochemistry analysis (n = 832) or unsuccessfully retrieved for TMA preparation (n = 360), the latter considered a surrogate marker for more scant tissue availability in preoperatively collected tissue. We have previously reported 36 that discordant histology in preoperative and post-operative assessments represent a group of patients with a distinct survival/ prognosis, significantly different from and intermediate between those with concordant low risk curettage and hysterectomy histology and those with concordant high risk features. This may be related to tumour heterogeneity. Curettage specimens, investigated in this study, probably reflect mostly the part of tumour protruding in the uterine cavity. Deeper parts of the tumour may have different histologic and molecular findings that will not necessarily be reflected in curettage specimens. Although tumour heterogeneity has not been systematically studied, data regarding correlation between discordant and concordant histology assessments and the immunohistochemical biomarkers ( Supplementary  Table 3 ) demonstrate that pathologic biomarker expressions are significantly higher in the group with discordant histology. This also suggests that biomarkers may aid in identifying this group of patients with poorer prognosis.
Receptor status and p53 expression have been evaluated as significant predictors of endometrial cancer survival in several retrospective studies. 37 A case-control study investigating curettings from 76 patients found p53 as independent predictor of metastatic nodes. 38 ER or PR status, not determined in their study, was a stronger predictor of lymph node metastasis and prognosis in our larger prospective study. Immunohistochemical expression of ER, PR and p53 has been evaluated in retrospective series to correlate well between curettage and final hysterectomy specimen, 20, 24 supporting preoperative staining as representative for status in tumour. Also in our series the hormone receptor status correlated well between curettage and hysterectomy specimens. The correlation for hormone receptor status in full sections versus TMA has earlier been studied comprehensively for breast cancer specimens, demonstrating a good concordance of 97% for ER staining and 98% for PR staining. 39 Of particular clinical relevance is our finding that double negative ER/PR significantly adds predictive and prognostic information for patients in the lowest risk group; with endometrioid grade 1 or 2 tumours subjected to lymphadenectomy, and also for patients without lymph node sampling, thus providing important information when addressing need for adjuvant therapy.
When evaluating cut-points, using lower quartiles, this corresponded to staining index 0-3 for ER and 0 for PR. The same cut-offs have been found in earlier data sets published from our group. 20, 24 In breast cancer where receptor negativity has been incorporated in treatment algorithms for several years there are large studies using 10% of cells staining positive as upper lim- 189  163  135  88  44  32  38  22  18  13  3  2   49  44  35  17  11  5  29  18  12  8  3 its for receptor negativity, which would correspond with staining index 3 (strong staining in less than 10%). 40 Thus further studies for standardization of assessments and cut points for new endometrial cancer biomarkers for implementation in the clinic will be important. Contrasting the treatment algorithms for breast cancer, 4 and despite several studies demonstrating a strong link between hormone receptor status and clinical phenotype in endometrial cancer, 41 biomarkers including ER and PR receptor status is still not routinely used to tailor endometrial cancer treatment. Even in five out of six randomised controlled trials regarding hormonal treatment, this information is not incorporated in the patient stratification. 42 Our prospective multicentre study demonstrates ER/PR status as an independent factor predicting lymph node metastasis as well as survival. Such classification has recently also been demonstrated of relevance for targeting systemic therapies in a metastatic setting. 41 This study was not designed to evaluate the role of lymphadenectomy in the treatment of endometrial cancer but offers an alternative approach with "molecular staging" of patients as a supplement to the well-established surgical staging for risk stratification. Based on our presented data we suggest that hormone receptor status in the future is integrated in randomised clinical trials of surgical and systemic therapies. ER/PR status in preoperative biopsies in addition to histopathologic classification improves the identification of low-and high-risk patients. A better preoperative differentiation of patients may also allow the allocation of those with low-risk and localised tumours for treatment at local hospitals while the more aggressive cancers can be handled adequately at more specialised centres. 
